Raloxifene hydrochloride

Description

Raloxifene hydrochloride · CAS 82640-04-8 · C28H27NO4S. UNII YX9162EO3I. Melting Point: 268-272; Melting Point: 143-147 °C; Melting Point: 143 - 147 °C.

Identification

Computed Descriptors

Physical & Chemical Properties

Physical description & handling notes

• Solid
• Crystals from acetone
• Crystals from methanol/water; mp: 258 °C; UV max (ethanol): 286 nm (epsilon 32800). Freely soluble in dimethylsulfoxide; sparingly soluble in methanol; slightly soluble in alcohol; very slightly soluble in water, isopropyl alcohol, octanol. Practically insoluble in ether, ethyl acetate /Raloxifene hydrochloride/
• Insoluble
• Stable under recommended storage conditions. /Raloxifene hydrochloride/
• 213.4 Ų [M-H]- [CCS Type: DT; Buffer gas: N2; Ionization: ESI-; Dataset: TOXCAST; Source Identifier: DTXSID1034181]

GHS Hazard Classification

Documented Uses

• Estrogen Antagonists; Selective Estrogen Receptor Modulators; Bone Density Conservation Agents
• Preparation ... C. D. Jones, European Patent Office patent 62503; idem, United States of America patent 4418068 (1982, 1983 both to Lilly).
• Indicated for the prevention and treatment of osteoporosis in postmenopausal women, as well as prevention and treatment of corticosteroid-induced bone loss. Indicated for the reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women with a high risk for invasive breast cancer.
• Raloxifene is an FDA-approved second-generation selective estrogen receptor modulator (SERM) that exerts estrogen-agonistic effects on bone, increasing bone mineral density and mass by decreasing bone resorption, and it is indicated for the treatment and prevention of postmenopausal osteoporosis. Raloxifene is also indicated for the reduction of risk of invasive breast cancer in postmenopausal women who are at high risk for invasive breast cancer or who have osteoporosis, with high risk defined as having 1 or more
• Evista is indicated for the treatment and prevention of osteoporosis in postmenopausal women. /Included in US product label/
• Evista is indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. /Included in US product label/

Synonyms

raloxifene; 84449-90-1; Keoxifene; Raloxifeno; Raloxifenum; Raloxifenum [Latin]; Raloxiphene; LY-139481; Eviden; Raxeto; LY 139481; DTXSID3023550; NSC-747974; YX9162EO3I; J22.982B; (2-(4-Hydroxyphenyl)-6-hydroxybenzo(b)thien-3-yl)(4-(2-(1-piperidinyl)ethoxy)phenyl)methanone

Frequently Asked Questions

What are the CAS number and molecular formula of Raloxifene hydrochloride?

CAS 82640-04-8; molecular formula C28H27NO4S; molecular weight — g/mol.

What other names is Raloxifene hydrochloride known by?

raloxifene, 84449-90-1, Keoxifene, Raloxifeno, Raloxifenum, Raloxifenum [Latin].

Is Raloxifene hydrochloride classified as hazardous?

Hazard statements reported: H302, H311, H315, H319, H332.

What are the key physical properties of Raloxifene hydrochloride?

Melting Point: 268-272; Melting Point: 143-147 °C; Melting Point: 143 - 147 °C; Solubility: 5.12e-04 g/L.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.